Literature DB >> 1294522

The comparative activity of fosfomycin trometamol against organisms isolated from infected urines.

D Greenwood1, R Edwards, J Brown, P Ridout.   

Abstract

Five hundred urinary pathogens, collected from patients of general practitioners and hospital in-patients, were identified and tested for susceptibility to fosfomycin, ampicillin, cephalexin, nalidixic acid, nitrofurantoin, trimethoprim and sulfamethoxazole. Overall, 83% of the isolates were sensitive to fosfomycin, comprising 89% of the out-patient strains and 77% of the in-patient isolates. This degree of sensitivity was similar to that of cephalexin, nalidixic acid and trimethoprim, but higher than that observed with ampicillin, nitrofurantoin and sulfamethoxazole. Fosfomycin generally showed a broad spectrum of activity, but was less active than some other compounds against Klebsiella spp. and streptococci. More than 70% of strains resistant to ampicillin, sulfamethoxazole or trimethoprim were sensitive to fosfomycin indicating that cross resistance is not presently a problem.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1294522     DOI: 10.1007/bf01710019

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  8 in total

1.  Phosphonomycin, a new antibiotic produced by strains of streptomyces.

Authors:  D Hendlin; E O Stapley; M Jackson; H Wallick; A K Miller; F J Wolf; T W Miller; L Chaiet; F M Kahan; E L Foltz; H B Woodruff; J M Mata; S Hernandez; S Mochales
Journal:  Science       Date:  1969-10-03       Impact factor: 47.728

2.  The microbiological and pharmacokinetic profile of an antibacterial agent useful for the single-dose therapy of urinary tract infection.

Authors:  R Slack; D Greenwood
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

3.  Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity.

Authors:  T Bergan
Journal:  Infection       Date:  1990       Impact factor: 3.553

4.  Fosfomycin trometamol: historical background and clinical development.

Authors:  G Gialdroni Grassi
Journal:  Infection       Date:  1990       Impact factor: 3.553

5.  Fosfomycin, antimicrobial activity in vitro and in vivo.

Authors:  S Goto
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

6.  Pharmacokinetic profile of fosfomycin trometamol (Monuril).

Authors:  G Segre; E Bianchi; A Cataldi; G Zannini
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

7.  Trometamol-fosfomycin (Monuril) bioavailability and food-drug interaction.

Authors:  E Bergogne-Bérézin; C Muller-Serieys; M L Joly-Guillou; N Dronne
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

8.  Plasmid-determined resistance to fosfomycin in Serratia marcescens.

Authors:  C Mendoza; J M Garcia; J Llaneza; F J Mendez; C Hardisson; J M Ortiz
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

  8 in total
  3 in total

1.  Antibiotic Selection for Urinary Tract Infection: New Microbiologic Considerations.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

Review 2.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Authors:  S S Patel; J A Balfour; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

3.  Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy.

Authors:  A Estebanez; R Pascual; V Gil; F Ortiz; M Santibáñez; C Pérez Barba
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-09-20       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.